Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema

FHS
March 5, 2024
9:50 am

EXN407 is the first topical SRPK1 inhibitor to demonstrate both safety and signals of biological response as monotherapy for these indications.

Targeting intracellular checkpoints to enhance NK cell immunotherapy

Natural killer (NK) cells are pivotal in the innate immune response against cancer and viral infections, with their presence in tumors correlating to better patient

November 28, 2024

What Investors Should See About Numinus Q3 Earnings

Psychedelics are the topic of today’s Trade to Black podcast. Host Shadd Dales, millennial entrepreneur Anthony Varrell, and lead financial writer Benjamin A. Smith put

July 19, 2023

The Push for Regulated Mushroom Sales in Vancouver

The TDR Three Takeaways on Mushrooms in Vancouver: Vancouver councillors aim to regulate magic mushroom sales to ensure safety and community protection. Proposed regulations seek

April 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.